* Monopar Therapeutics Inc reported a quarterly adjusted loss of 37 cents per share for the quarter , higher than the same quarter last year, when the company reported EPS of -70 cents. The mean expectation of three analysts for the quarter was for a loss of 48 cents per share. Wall Street expected results to range from -52 cents to -40 cents per share.
* Reported revenue was zero; analysts expected zero.
* Monopar Therapeutics Inc's reported EPS for the quarter was a loss of 37 cents.
* The company reported a quarterly loss of $1.3 million.
* Monopar Therapeutics Inc shares had risen by 133.4% this quarter and gained 824.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 1.4% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Monopar Therapeutics Inc is 15.00 This summary was machine generated from LSEG data November 8 at 04:20 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.48 -0.37 Beat
Jun. 30 2024 -0.47 -0.50 Missed
Mar. 31 2024 -0.60 -0.50 Beat
Dec. 31 2023 -0.77 -0.60 Beat
Comments